No Endotamponade for Macular Hole Repair: the NEMAR Study
Launched by CHINESE UNIVERSITY OF HONG KONG · Apr 1, 2025
Trial Information
Current as of June 14, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The NEMAR Study is investigating two different surgical techniques for repairing a condition called a macular hole, which is a serious eye problem that can lead to vision loss. The standard method, known as conventional surgery, involves removing the damaged tissue and using a gas bubble to help the eye heal. However, this study is exploring a new technique that skips the gas bubble altogether, which could make recovery easier for patients. Researchers want to see if this new approach is just as effective and safe as the traditional method.
To participate in the study, individuals must be at least 18 years old and have a full-thickness macular hole in one eye. Those who have had prior eye surgeries, certain eye diseases, or specific anatomical conditions may not be eligible. Participants will undergo one of the two surgical techniques and will be monitored post-surgery to evaluate their recovery and vision improvement. This study aims to provide valuable information that could potentially change how macular holes are treated in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \>= 18 years
- • Presence of full thickness macular hole in one eye (defined as full thickness discontinuity of euro-sensory retina at the macula on optical coherence tomography)
- • Able to comply to post-operative posture
- Exclusion Criteria:
- • Fellow eye enrolled in the study
- • Eyes that underwent previous macular surgery
- • Presence of maculopathy other than macular hole, api-retinal membrane or myopic maculopathy. For example, age-related macular degeneration, diabetic macular edema or pre-existing macular scar
- • Axial length \>/= 30mm or presence of significant myopic chorio-retinal atrophy involving the fovea
- • Minimum linear diameter \>/=1000µm
- • Presence of contraindications to intraocular gas, such as advanced glaucoma or uncontrolled glaucoma
- • Patients who are unable to give informed consent
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Simon KH Szeto, FCOphth(HK)
Principal Investigator
Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported